The World Health Organization (WHO) announced on Monday that it has approved the Bavarian Nordic’s Jynneos vaccine for adolescents aged 12 to 17 years, a demographic identified as particularly vulnerable to mpox outbreaks.
The decision, reported today by Reuters, follows the WHO’s August announcement of a renewed global public health emergency due to mpox. The move aims to widen access to the vaccine amid rising concerns over the viral infection.
